Repligen (RGEN) Financials, Dividends & Stock Info
Explore comprehensive financial data for Repligen, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (572 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Repligen (RGEN) is a biotechnology company. The company reports annual revenue of $141M and net loss of $26M. Its profit margin is -18.1%.
Repligen Key Financials
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Repligen Financial Health ScoreFY2025
Moderate health; several metrics need attention
+10 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Negative profit margin: -18.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Repligen Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
About Repligen
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin Marginsvs 18.1% sector median / 15.0% avg
Currently operating at a loss of 18 cents per dollar of revenue.
Profit margin 220% below sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Repligen 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $30.6M(-70.7%) | $104.5M(+53.4%) |
| Net Income | $48.9M(+291.6%) | $-25,514,000(-171.7%) | $35.6M(-80.9%) | $186.0M(+45.0%) | $128.3M(+114.1%) | $59.9M(+179.9%) | $21.4M(+28.8%) | $16.6M(-41.4%) | $28.4M(+142.7%) | $11.7M(-27.4%) |
| Total Assets | $2.9B | $2.8B | $2.8B | $2.5B | $2.4B | $1.9B | $1.4B | $774.6M | $743.5M | $288.9M |
| Total Debt | $542.2M | $525.6M | - | - | - | - | - | - | - | - |
| Total Equity | $2.1B | $2.0B | $2.0B | $1.9B | $1.8B | $1.5B | $1.1B | $615.6M | $591.5M | $168.8M |
| Profit Margin | - | - | - | - | - | - | - | - | 92.7% | 11.2% |
| ROE | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% | 3.9% | 2.0% | 2.7% | 4.8% | 6.9% |
| ROA | 1.7% | -0.9% | 1.3% | 7.4% | 5.4% | 3.1% | 1.5% | 2.1% | 3.8% | 4.0% |
Quarterly Financials
Last 8 quarters| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Net Income | $14.9M | $14.9M | $5.8M | $-654,000 | $5.7M | $3.3M | $16.9M | - |
| Total Assets | $2.9B | $2.9B | $2.9B | $2.8B | - | - | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Repligen Free Cash Flow & Dividend Coverage
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.5M | $17.5M | $32.8M | $67.2M | $62.6M | $119.0M | $172.1M | $113.9M | $175.4M | $117.4M |
| CapEx | -$4.3M | -$5.5M | -$10.6M | -$18.5M | -$22.5M | -$67.1M | -$84.8M | -$36.2M | -$25.7M | -$23.5M |
| Free Cash Flow | $3.2M | $12.0M | $22.1M | $48.7M | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
| FCF Margin | 3.1% | 39.2% | - | - | - | - | - | - | - | - |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Repligen Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for RGEN.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Repligen FAQ
What is Repligen's annual revenue?
Repligen (RGEN) reported $141 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Repligen profitable?
Repligen reported a net loss with a -18.1% profit margin, totaling $26 million in net losses (TTM). All figures from SEC EDGAR 10-K filings.
Does Repligen pay dividends?
No, Repligen (RGEN) does not currently pay dividends to shareholders.
What is Repligen's financial health score?
Repligen has a financial health score of 61/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Repligen financial data are available?
10 years of financial data are available for Repligen from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.